CSSPF (NIOX Group) ROCE %: 15.52% (As of Dec. 2025)


CSSPF NIOX Group PLC CSSPF
77 GF Score
Price $0.80
GF Value $1.21
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is NIOX Group ROCE %?

NIOX Group CSSPF 77 ROCE % is 15.52% as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NIOX Group's annualized ROCE % for the quarter that ended in Dec. 2025 was 15.52%.

NIOX Group  (OTCPK:CSSPF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NIOX Group ROCE % Related Terms

NIOX Group ROCE % Historical Data

* Premium members only.

The historical data trend for NIOX Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NIOX Group ROCE % Chart

NIOX Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.62 12.34 4.93 10.92 17.91

NIOX Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.78 10.84 9.51 19.80 15.52
CSSPF
77GF Score
NIOX Group PLC CSSPF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NIOX Group ROCE % Calculation

NIOX Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=14.993/( ( (86.473 - 10.24) + (102.008 - 10.843) )/ 2 )
=14.993/( (76.233+91.165)/ 2 )
=14.993/83.699
=17.91 %

NIOX Group's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=13.922/( ( (96.336 - 8.141) + (102.008 - 10.843) )/ 2 )
=13.922/( ( 88.195 + 91.165 )/ 2 )
=13.922/89.68
=15.52 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 15.52% mean?
NIOX Group (CSSPF) has a ROCE % of 15.52% as of Dec. 2025.
Is NIOX Group's ROCE % too high?
NIOX Group's current ROCE % is 15.52%. The Medical Devices & Instruments industry median ROCE % is 2.23. NIOX Group's value of 15.52% is 596% above this industry median. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's ROCE % compare to ABT and SYK?
NIOX Group's ROCE % of 15.52% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. NIOX Group's value of 15.52% is 596% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current ROCE % of 15.52% is 596% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current ROCE % is 15.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current ROCE % is 15.52% and 596% above the Medical Devices & Instruments industry median of 2.23. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For NIOX Group (CSSPF), the current ROCE % is 15.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NIOX Group (CSSPF) Overvalued in 2026?

Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued. The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21. GuruFocus considers NIOX Group to be Significantly Undervalued.

Key valuation signals for CSSPF:

  • ROCE %: 15.52%
  • GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
  • GF Score™: 77/100 with 1 warning sign
  • Industry Position: 596% above the Medical Devices & Instruments median

No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NIOX Group Business Description

Other Exchanges NIOXl:UKNIOX:UK82C:Germany
Address 1 Robert Robinson Avenue, Magdalen Centre, The Oxford Science Park, Oxford, GBR, OX4 4GA
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score

Get the complete analysis for CSSPF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.80
Price
$1.21
GF Value